VEGFR3 and CD31 as prognostic factors in renal cell cancer

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 921-927

  Virman, Juha Pekka ^a,b   Bono, Petri ^c   Luukkaala, Tiina ^d   Sunela, Kaisa ^b   Kujala, Paula ^b   Kellokumpu Lehtinen, Pirkko Liisa ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d PIRKANMAA HOSPITAL DISTRICT   (Finland)

Author keywords

CD 31; Prognostic factor; Renal cell cancer (RCC); Vascular endothelial growth factor receptor (VEGFR)

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; VASCULOTROPIN RECEPTOR 3; TUMOR MARKER; VEGFR3 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; SURVIVAL TIME; KIDNEY TUMOR; METABOLISM; PROGNOSIS;

AGED; ANTIGENS, CD31; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84923676048     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Roy H, Bhardwaja S and Ylä-herttuala S: Biology of vascular endothelial growth factors. FEBS Letters 580: 2879-2887, 2006
2. Tugues S, Koch S, Gualandi L, Li X and Glaesson-Welsh L: Vascular endothelial growth factors and receptors: Antiangiogenic therapy in the treatment of cancer. Molecul aspects of med 32: 88-101, 2011.
3. Ferrara N, Gerber H-P and LeCouter J: The biology of VEGF and its receptors. Natural Med 31: 669-676, 2003.
4. Witmer AN, Vrensen GFJM, Van Noorden CJF and Schlingemann RO: Vascular endothelial growth factor and angio genesis in eye disease. Prog in Retinal and Eye Res 22: 1-29, 2003.
5. Alitalo A and Detmar M: Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 31: 4499-4508, 2012.
6. Jiang Y, Liang G, Wang L, Jiang J, Du G and Huang Y: Association between vascular endothelial growth factor +936 C/T gene polyformism and age-related macular degeneration. J of Int Med Res 41: 317-324, 2013.
7. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G and Ljungberg B: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. Br J of Urol 93: 297-302, 2004
8. Yang C-C, Chu K-C and Yeh W-M: Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement. J of Clin Lab Analyses 17: 85-89, 2003.
9. Abe H and Kamai T: Recent advances in the treatment of metastatic renal cell carcinoma. Int J of Urol 20: 944-955, 2013.
10. Kim WY and Kaelin WG: Role of VHL gene mutation in human cancer. J of Clin Oncol 22 : 4991-5004, 2004.
11. Nickerson ML1, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM and Moore LE. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors: Clin Cancer Res 14: 4726-4734, 2008.
12. DePrimo S, Bello C, Smeraglia J, Baum C, Spinella D, Rini B, Michaelson M and Motzer R: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J of Translational Med 5 : 32, 2007.
13. Tomita Y, Uemura H, Fujimoto H, Kanayama H-O, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S and Akaza H: Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J of Cancer 47: 2592-2602, 2001.
14. Funakoshi T, Lee C-H and Hsieh J: A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treatment Rev 40: 533-547, 2014.
15. Sharma B, Singh N, Gupta N, Lal P, Pande S and Chauhan S: Diagnostic modalities of precancerous and cancerous cervical Lesions with special emphasis on CD31 angiogenesis factor as a marker. Pathol Res Int 2013: 243168. p5, 2013.
16. Ibrahim S, Jilani I, O'Brien S, Rogers A, Manshouri T, Giles F, Faderl S, Thomas D, Kantarjian H, Keating M and Albitar M: Clinical prevalence of expression of the CD31 liganf for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer 97: 1914-1919, 2003.
17. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljundberg B and Rasmuson T: Evaluation of CD31 (PECAM-1) ecpression using tissue microarray in patients with renal cell cancer. Tumor Biol 28: 158-164, 2007.
18. Biswas S, Charleswo JS, Turner GDH, Leek R, Thamboo TP, Cambo L, Turley H, Dildey P, Protheroe A, Granston D, Gatter KC, Pezzella F, and Harris AL: CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC. Carcinogensis 33: 1717-1725, 2012.
19. Sunela KL, Kataja MJ, Lehtinen ET, Salminen TK, Kujala PM, Virman JP and Kellokumpu-Lehtinen P: Prognostic factors and long-term survival in renal cell cancer patients. Scand J Urol Nephrol 43: 454-460, 2009.
20. Jacobsen J, Rasmuson T, Grankvist T and Ljundberg B: Vascular endothelial growth factor as prognostic factor on renal cell carcinoma. J Urol 1: 242-247, 2000.
21. Virman J, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K and Kellokumpu-Lehtinen P-L: Claudins as prognostic factors for renal cell cancer. Anticancer Res 34: 4181-4187, 2014.
22. Sobin LH and Wittekind CH:TNM Classification of Malignant Tumours. 6th ed. Hoboken NJ: John Wiley & Sons; Renal cell carcinoma staging (TNM), 2002.
23. Fuhrman S, Lasky L and Limas C: Prognostic significance of morphologic parametres in renal cell carcinoma. AM J Surg Pathol 6: 665, 1982.
24. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E and Zbar B: The Heidelberg classification of renal cell tumours. J Pathol 183: 131-133, 1997.
25. Bono P, Waseniuns VM, Heikkilä P, Lundin J, Jackson DG and Joensuu H: High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Can Res 10: 7144-7149, 2004.
26. Finley DS, Pantuck AJ and Belldergun: Tumor biology and prognostic factors in renal cell carcinoma. The Oncologist 16: 4-13, 2011.
27. Conti A, Santoni M, Amantini C, Burattini L, Berardi R, Santoni G, Cascinu S and Muzzonigro: Progress of molecular targeted therapies for advanced renal cell carcinoma. BioMed Res Int 419176: 9p, 2013.
28. Garcia-Donas, eonardo-Garcia LJ, González del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, Bellmunt J, Mellado R, Puente J, Moreno F, Font A, Hernando S, Robledo M and Rodriguez-Antona C: Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann of Oncol 24: 2409-2414, 2013.
29. Bieber S, Herrmann E, Köpke T, Neumann J, Eltze E, Hertle L and Wülfing: Lymphangiogenesis in kidney cancer: Expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma. Oncol rep 20: 721-725, 2008.
30. Zhang YH, Diao L, Yang Q, Duo J, Liu YX, Liu SX and Yao X: Expression of VEGFR-2 and VEGFR-3 in papillary renal cell carcinoma and their relationship with prognosis. Zonghua zhong liu za zhi (Chin J Oncol) 32: 752-756, 2010.
31. Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE,Michaelson MD, Négrier S,Kim S, Huang X, Williams JA, Eisen T and Motzer RJ: Circulating proteins as potential biomarkers of sunitiniband interferon-α efficacy in treatment.naive patients with metastatic renal cell carcinoma. Cancer Chemoteh Pharmacol 73 : 151-161, 2014.
32. Taskinen M, Jantunen E, Kosma V-M, Bono P, Karjalainen-Lindsberg M-J and Leppä S: Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunotherapy. Eur J Cancer 46: 2506-2512, 2010.
33. Zheng W, Aspelund A and Alitalo K: Lymphangiogenic factors, mechanism, and applications. J Clin Invest 124: 878-887, 2014.